Open access
Jul 2026
Cost-benefit analysis of a potential hepatitis C vaccine: a modelling study.
In the context of heterogeneous treatment scale-up among countries, a hepatitis C vaccine is likely to have a positive return-on-investment when used to vaccinate populations at highest risk of infection.
Farah Houdroge, Phillip Luong, Jessica Zuk et al.
· BMC Infectious Diseases · 0 citations